Engineering a Stable Tegoprazan Nanosuspension System for Enhanced Dissolution and Oral Bioavailability
Pharmaceutics · 05.11.2026 · 18 (11) · 1436
DOI: 10.3390/pharmaceutics18111436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 05.11.2026. Verfasst von Min Gyeong Jeong und 5 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background/Objectives: The aim of this study was to design a nanosuspension (NS) of tegoprazan (TPZ), a novel potassium-competitive acid blocker (P-CAB), to overcome its low aqueous solubility and improve oral absorption.
Methods
TPZ NSs were prepared using a lab-scale bead-milling technique. Subsequently, their physicochemical properties, in vitro dissolution profiles, storage stability, and in vivo pharmacokinetic profiles were evaluated.
Results
Among various screened stabilizers, polyvinyl alcohol was selected as the suspending agent due to its favorable physicochemical stability. The optimized NS exhibited a mean particle size of approximately 270 nm and a zeta potential of −12.1 mV, preserving the crystalline state of TPZ. In vitro dissolution studies revealed that the NS and its freeze-dried form (NS-FD) markedly enhanced drug dissolution across all tested dissolution media (pH 1.2, 4.0, 6.8, and distilled water) compared to the raw drug material. Furthermore, the NS formulations remained physically and chemically stable for up to 12 weeks under long-term and accelerated storage conditions (25 °C/60% relative humidity (RH) and 40 °C/75% RH). In vivo pharmacokinetic studies in male Sprague–Dawley rats revealed that the oral TPZ NS resulted in approximately a 2.1-fold increase in systemic exposure compared to the raw material and microsuspension.
Conclusions
These findings suggest that TPZ NS is a promising strategy to enhance the oral absorption of P-CAB, using a simple, organic-solvent-free fabrication process.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Jeong, M. G., Yang, I. G., Baek, Y. J., Kim, S. H., Kang, M. J., & Choi, M. (2026). Engineering a Stable Tegoprazan Nanosuspension System for Enhanced Dissolution and Oral Bioavailability. Pharmaceutics, 18(11), 1436. https://doi.org/10.3390/pharmaceutics18111436
Vancouver
Jeong MG, Yang IG, Baek YJ, Kim SH, Kang MJ, Choi M. Engineering a Stable Tegoprazan Nanosuspension System for Enhanced Dissolution and Oral Bioavailability. Pharmaceutics. 2026;18(11):1436. doi:10.3390/pharmaceutics18111436
BibTeX
@article{Jeong2026,
author = {Jeong, Min Gyeong and Yang, In Gyu and Baek, Yeon Ju and Kim, Sun Ho and Kang, Myung Joo and Choi, Min-Koo},
title = {Engineering a Stable Tegoprazan Nanosuspension System for Enhanced Dissolution and Oral Bioavailability},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1436},
doi = {10.3390/pharmaceutics18111436}
}
EUVIMED